BeBetter Pharmaceuticals

BeBetter Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the discovery and development of innovative small molecule drugs. The company focuses on high-unmet-need areas including oncology, autoimmune disorders, and metabolic diseases. Its lead programs include BEBT-908, a dual PI3K/HDAC inhibitor for hematologic malignancies, and BEBT-209, a CDK4/6 inhibitor for breast cancer. BeBetter utilizes a chemistry-driven approach to design differentiated therapies with improved efficacy and safety profiles. The company maintains a robust pipeline with several candidates in late-stage clinical trials and has established a strong presence in the Chinese biotech ecosystem.